We believe that Natural Killer cells have the potential to revolutionize cancer immunotherapy towards a cure.
Stem cell precision engineering and highly-scalable manufacturing allow us to create differentiated cell therapeutics and democratize their use and availability. As a result, physicians will have the option to introduce curative off-the-shelf therapies as a first line of defense and on an outpatient basis.
Our Flex-NK™ bispecific antibodies offer the potential for enhanced cytotoxicity in patients with a large number of functional endogenous or allogeneic natural killer cells, providing an option for even earlier intervention.
We aim to expand cell therapy beyond hematological malignancies to solid tumors, addressing key unmet medical needs and offering its benefits to as many patients as possible.
Cytovia aims to develop its medicine globally, with operations in the US and Europe and access to China through our CytoLynx Partnership.